At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Jun 14, 2026 at 10:21 ET
Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long-term Phase 2 data for barzolvolimab in CSU, showing durable angioedema improvements off-treatment through Week 76. Phase 3 topline data is expected in Q4 2026, with a BLA submission planned for 2027.
- Q1 2026 EPS of -$1.18 missed consensus of -$1.07 (-10.8% miss)
- Revenue of $859K (consensus $859K), in line
- Phase 2 barzolvolimab data showed up to 64% of angioedema patients remained symptom-free 7 months after last dose
- Phase 3 CSU trials fully enrolled with 1,939 patients; topline data expected Q4 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access